Published in Ann Surg on November 01, 2002
Primary hyperparathyroidism: an analysis of failure of parathyroidectomy. World J Surg (2014) 2.09
A rising ioPTH level immediately after parathyroid resection: are additional hyperfunctioning glands always present? An application of the Wisconsin Criteria. Ann Surg (2010) 1.71
Radioguided parathyroidectomy is equally effective for both adenomatous and hyperplastic glands. Ann Surg (2003) 1.29
Nuclear imaging and minimally invasive surgery in the management of hyperparathyroidism. J Nucl Med (2008) 1.11
Feasibility of rapid parathormone assay for enabling minimally invasive parathyroid excision. Indian J Surg (2012) 1.01
Minimally invasive video-assisted parathyroidectomy versus open minimally invasive parathyroidectomy for a solitary parathyroid adenoma: a prospective, randomized, blinded trial. World J Surg (2006) 0.94
Secondary and tertiary hyperparathyroidism: the utility of ioPTH monitoring. World J Surg (2010) 0.84
Changes in swallowing-related quality of life after parathyroidectomy for hyperparathyroidism: a prospective cohort study. Oncologist (2012) 0.82
Radioguided parathyroidectomy for hyperparathyroidism in the reoperative neck. Surgery (2009) 0.81
Patients with symptomatic primary hyperparathyroidism: an anaesthetic challenge. Indian J Anaesth (2009) 0.80
A retrospective case-controlled study of video-assisted versus open minimally invasive parathyroidectomy. Wideochir Inne Tech Maloinwazyjne (2014) 0.79
Influence of morbid obesity on parathyroidectomy outcomes in primary hyperparathyroidism. Am J Surg (2010) 0.78
Use of the gamma probe to identify multigland disease in primary hyperparathyroidism. Int J Endocr Oncol (2016) 0.75
Role of cervical ultrasonography in primary hyperparathyroidism. Indian J Radiol Imaging (2008) 0.75
Radioguided parathyroidectomy for tertiary hyperparathyroidism. J Surg Res (2015) 0.75
Does levothyroxine administration impact parathyroid localization? J Surg Res (2015) 0.75
Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg (2002) 3.14
Outpatient minimally invasive parathyroidectomy: a combination of sestamibi-SPECT localization, cervical block anesthesia, and intraoperative parathyroid hormone assay. Surgery (1999) 2.28
Ambulatory parathyroidectomy for primary hyperparathyroidism. Arch Surg (1996) 1.98
Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg (2002) 1.87
One hundred consecutive minimally invasive parathyroid explorations. Ann Surg (2000) 1.82
Parathyroidectomy in Maryland: effects of an endocrine center. Surgery (1996) 1.61
Effect of minimally invasive radioguided parathyroidectomy on efficacy, length of stay, and costs in the management of primary hyperparathyroidism. Ann Surg (2000) 1.45
Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay. Ann Surg (1999) 1.33
Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma. Ann Surg (2002) 1.30
Parathyroidectomy in the elderly: do the benefits outweigh the risks? World J Surg (1998) 1.22
Parathyroid surgery using monitored anesthesia care as an alternative to general anesthesia. Am J Surg (1996) 0.97
Is unilateral neck exploration for parathyroid adenoma appropriate? Adv Surg (2000) 0.92
Minimally invasive parathyroid surgery in 103 patients with local/regional anesthesia, without exclusion criteria. Surgery (2002) 0.89
Carcinoid tumors. Oncologist (2008) 2.86
Is there still a glass ceiling for women in academic surgery? Ann Surg (2011) 2.33
Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab (2007) 2.26
Using body mass index to predict optimal thyroid dosing after thyroidectomy. J Am Coll Surg (2013) 2.10
Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem (2006) 2.05
Pheochromocytoma: current approaches and future directions. Oncologist (2008) 2.05
Incidence and localization of ectopic parathyroid adenomas in previously unexplored patients. World J Surg (2013) 1.96
Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist (2007) 1.96
Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther (2007) 1.85
Current management of medullary thyroid cancer. Oncologist (2008) 1.80
Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist (2007) 1.78
Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid (2013) 1.77
Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2003) 1.76
Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res (2007) 1.75
A rising ioPTH level immediately after parathyroid resection: are additional hyperfunctioning glands always present? An application of the Wisconsin Criteria. Ann Surg (2010) 1.71
Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas (2013) 1.65
Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg (2011) 1.64
Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.59
Isolated adrenal mass in patients with a history of cancer: remember pheochromocytoma. Ann Surg Oncol (2007) 1.56
Remnant uptake as a postoperative oncologic quality indicator. Thyroid (2013) 1.56
The utility of frozen section evaluation for follicular thyroid lesions. Ann Surg Oncol (2004) 1.53
ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther (2005) 1.53
25-hydroxyvitamin D status does not affect intraoperative parathyroid hormone dynamics in patients with primary hyperparathyroidism. Ann Surg Oncol (2010) 1.50
Can thallium-pertechnetate subtraction scanning play a role in the preoperative imaging for minimally invasive parathyroidectomy? Clin Nucl Med (2004) 1.47
Radioguided parathyroidectomy in patients with familial hyperparathyroidism. Ann Surg Oncol (2006) 1.46
Thyroidectomy decreases snoring and sleep apnea symptoms. Thyroid (2012) 1.46
Carcinoid tumors. Surg Oncol Clin N Am (2006) 1.45
Pancreatic endocrine tumors. J Surg Res (2004) 1.42
Tertiary hyperparathyroidism: is less than a subtotal resection ever appropriate? A study of long-term outcomes. Surgery (2009) 1.42
Clinical efficacy of fine-needle aspiration biopsy of thyroid nodules in males. J Surg Res (2009) 1.42
The necessity and reliability of intraoperative parathyroid hormone (PTH) testing in patients with mild hyperparathyroidism and PTH levels in the normal range. World J Surg (2011) 1.42
All thyroid ultrasound evaluations are not equal: sonographers specialized in thyroid cancer correctly label clinical N0 disease in well differentiated thyroid cancer. Ann Surg Oncol (2014) 1.41
How Well Does Renal Transplantation Cure Hyperparathyroidism? Ann Surg (2015) 1.40
Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann Surg (2008) 1.39
Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab (2005) 1.39
The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery (2003) 1.37
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery (2006) 1.34
Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin North Am (2009) 1.34
Treatment of advanced carcinoid tumors. Curr Opin Oncol (2006) 1.32
Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) (2008) 1.31
The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell (2013) 1.30
Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma. Ann Surg (2002) 1.30
Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery (2005) 1.28
Radioguided parathyroidectomy via VATS combined with intraoperative parathyroid hormone testing: the surgical approach of choice for patients with mediastinal parathyroid adenomas? J Bone Miner Res (2002) 1.22
Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg (2006) 1.22
Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. Oncologist (2008) 1.21
What is the clinical significance of an elevated parathyroid hormone level after curative surgery for primary hyperparathyroidism? Ann Surg (2009) 1.20
Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells. J Gastrointest Surg (2007) 1.19
Gastrointestinal carcinoid tumors: factors that predict outcome. World J Surg (2004) 1.18
The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs (2006) 1.17
Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger. Arch Surg (2009) 1.17
Is minimally invasive parathyroidectomy associated with greater recurrence compared to bilateral exploration? Analysis of more than 1,000 cases. Surgery (2012) 1.17
New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin (2013) 1.16
Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method. Cancer (2010) 1.15
Medical student operative experience correlates with a match to a categorical surgical program. Am J Surg (2003) 1.15
Total thyroidectomy: a safe and effective treatment for Graves' disease. J Surg Res (2011) 1.15
Impact of lymph node ratio on survival in papillary thyroid cancer. Ann Surg Oncol (2012) 1.14
Postoperative parathyroid hormone testing decreases symptomatic hypocalcemia and associated emergency room visits after total thyroidectomy. Surgery (2010) 1.14
Contralateral papillary thyroid cancer: does size matter? Am J Surg (2009) 1.14
Radioguided parathyroidectomy in patients with secondary and tertiary hyperparathyroidism. Surgery (2003) 1.12
Why do students choose careers in surgery? J Surg Res (2004) 1.12
MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer (2010) 1.11
Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol (2012) 1.10
Parathyroid hormone deficiency after total thyroidectomy: incidence and time. J Surg Res (2010) 1.10
Calciphylaxis in the absence of end-stage renal disease. Endocr Pract (2006) 1.09
New trends in parathyroid surgery. Curr Probl Surg (2010) 1.09
Lithium ions: a novel treatment for pheochromocytomas and paragangliomas. Surgery (2007) 1.09
Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery (2008) 1.08
The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res (2007) 1.08
In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid (2011) 1.08
Creation of a "Wisconsin index" nomogram to predict the likelihood of additional hyperfunctioning parathyroid glands during parathyroidectomy. Ann Surg (2013) 1.07
Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. Curr Opin Investig Drugs (2008) 1.06
Radioguided parathyroidectomy for recurrent hyperparathyroidism caused by forearm graft hyperplasia. J Bone Miner Res (2003) 1.06
In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anticancer Drugs (2006) 1.06
Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid. Ann Surg Oncol (2008) 1.06
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist (2011) 1.05
Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta. Mol Cancer Ther (2009) 1.05
Thyroid hormone replacement after thyroid lobectomy. Surgery (2009) 1.05
Palliation of advanced thyroid malignancies. Surg Oncol (2007) 1.05
Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study. Ann Surg Oncol (2014) 1.04
Down-regulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma. Am J Transl Res (2009) 1.04
Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res (2006) 1.04
Are there predictors of malignancy in patients with multinodular goiter? J Surg Res (2011) 1.03
The surgical management of Graves' disease. J Surg Res (2006) 1.03
Fine-needle aspiration optimizes surgical management in patients with thyroid cancer. Ann Surg Oncol (2006) 1.02
What is the biology and optimal treatment for papillary microcarcinoma of the thyroid? J Surg Res (2006) 1.02
The utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing. Ann Surg (2007) 1.01
ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells. J Surg Res (2006) 1.01
Predictors of recurrence in primary hyperparathyroidism: an analysis of 1386 cases. Ann Surg (2014) 1.01
Advances in surgical therapy for thyroid cancer. Nat Rev Endocrinol (2011) 1.01
Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth. Mol Cancer Ther (2013) 1.01
Effective surgical residents strongly influence medical students to pursue surgical careers. J Am Coll Surg (2007) 1.01
Controversies in the surgical management of newly diagnosed and recurrent/residual thyroid cancer. Thyroid (2009) 1.01
What is the optimal treatment for children with primary hyperparathyroidism? J Pediatr Surg (2010) 1.00
Same-day thyroidectomy program: eligibility and safety evaluation. Surgery (2012) 1.00
Risks and consequences of incidental parathyroidectomy during thyroid resection. ANZ J Surg (2007) 1.00
Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J Am Coll Surg (2009) 1.00
A multi-institutional international study of risk factors for hematoma after thyroidectomy. Surgery (2013) 0.99
Current understanding and management of medullary thyroid cancer. Oncologist (2013) 0.99
Are surgical progeny more likely to pursue a surgical career? J Surg Res (2008) 0.99